Diffuse large B-cell lymphoma with phenotype switch, anaplastic features and aberrant T-cell marker expression during disease evolution

[摘要] A 41-year-old man was referred to our institution for relapsed diffuse large B-cell lymphoma (DLBCL). He was diagnosed with DLBCL,non-germinal center B-cell (non-GCB) immunophenotype at an outside hospital and received R-EPOCH for 6 cycles and reached completeremission. He relapsed 3 months later and received RICE (Rituximab,Ifosfamide, Carboplatin and Etoposide) chemotherapy and autologous stem cell transplant for persistent disease, then further receivedDHAP, and anti-CD19-CAR T-cell therapy combined with ibrutinib.He now progressed with extensive lymphadenopathy and extranodalinvolvement.

[关键词] DLBCL;phenotype switch;clonal evolution;anaplastic;aberrant T-cell marker expression